SAN DIEGO, July 1, 2015 /PRNewswire/ -- OncoSec Medical Inc.
("OncoSec") (Nasdaq: ONCS), a company developing DNA-based
intratumoral cancer immunotherapies, today announced that CEO and
President Punit Dhillon will ring
The Nasdaq Opening Bell in celebration of the Company's listing to
The Nasdaq Stock Market at 9:30 am ET
on July 7, 2015 at The Nasdaq
MarketSite in New York City.
"On behalf of all of our dedicated employees, investors, and
stakeholders, we are honored to open the Nasdaq to celebrate
OncoSec's listing on this leading stock exchange," said
Punit Dhillon, CEO and President of
OncoSec. "As a leader in intratumoral immunotherapy, our listing on
Nasdaq marks another important milestone for OncoSec over the past
year. We will continue to advance our intratumoral immunotherapies
in the clinic with the goal of one day benefiting cancer patients
everywhere."
OncoSec invites investors and the general public to view to the
live webcast. At the time of the event, the webcast will be
available via the following link:
https://new.livestream.com/nasdaq/live. An archived version of the
webcast will be available for 90 days on OncoSec's website:
http://www.oncosec.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a
biopharmaceutical company developing its investigational
ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core
technology is designed to enhance the local delivery and uptake of
DNA IL-12 and other DNA-based immune-targeting agents. Clinical
studies of ImmunoPulse™ have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response limiting the systemic
toxicities associated with other treatments. OncoSec's lead program
evaluating ImmunoPulse™ for the treatment of metastatic melanoma is
currently in Phase II development, and is being conducted in
collaboration with several prominent academic medical centers. As
the company continues to evaluate ImmunoPulse™ in its current
indications, it is also focused on identifying and developing new
immune-targeting agents, investigating additional tumor
indications, and evaluating combination-based immunotherapy
approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward-looking statements."
Forward-looking statements are based on management's current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Inc.
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-medical-to-ring-the-nasdaq-stock-market-opening-bell-300107373.html
SOURCE OncoSec Medical Inc.